News Releases

Date	Title and Summary	View
Oct 16, 2020	Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA®▼ (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union (EU)
Oct 15, 2020	New First-in-Class Phase 3 Data Demonstrate TREMFYA® (guselkumab) Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis
Oct 15, 2020	Johnson & Johnson to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
Oct 13, 2020	Johnson & Johnson Reports 2020 Third-Quarter Results - Sales of $21.1 billion reflecting an overall and operational increase of 1.7%, and adjusted operational increase of 2.0% despite the estimated negative impact of the COVID-19 pandemic - EPS of $1.33 increased 101.5%; adjusted EPS of $2.20 increased 3.8%* - Company increasing guidance for
Oct 12, 2020	STELARA® (ustekinumab) Five-Year Results Presented from Long-term Extension Study of Clinical Response and Remission in Patients with Moderate to Severe Crohn’s Disease
Oct 12, 2020	TREMFYA® (guselkumab) Induces Clinical and Endoscopic Improvements in Patients with Moderately to Severely Active Crohn’s Disease based on Interim Results from Phase 2 Study
Oct 08, 2020	Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate Agreement provides option for European Union Member States to secure up to 200 million additional doses for a total of up to 400 million doses NEW BRUNSWICK, N.J., Oct. 8, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on
Oct 06, 2020	Biosense Webster Receives FDA Approval for THERMOCOOL SMARTTOUCH® SF Ablation Catheter for the Treatment of Persistent Atrial Fibrillation
Oct 01, 2020	Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc. Acquisition broadens Janssen's leadership in autoimmune diseases and provides a major catalyst for sustained growth NEW BRUNSWICK, N.J. , Oct. 1, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc.
Sep 30, 2020	SIMPONI ARIA® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older